Abstract:
A novel 1,2,4-thiadiazolidine-3,5-dione compound is provided to show excellent activity and enzyme selectivity on Lck SH2, thereby being usefully used for treating and preventing inflammation related diseases such as rheumatoid arthritis with high selectivity without side effects. A pharmaceutical composition for treating and preventing a disease induced by inflammation comprises a 1,2,4-thiadiazolidine-3,5-dione compound represented by a formula(1) or a pharmaceutically acceptable salt thereof as an effective ingredient. In the formula(1), A is linear or branched saturated or unsaturated C1-7 alkyl, indenyl, (C1-7)alkoxycarbonyl(C1-7)alkyl, phenyl, benzyl or C2H5(C=O)HR2R3(wherein A may be substituted by halogen, carboxyl, C1-7 alkoxycarbonyl, C1-7 alkoxy, nitro or hydroxy when A is alkyl, phenyl or benzyl); R1 is H, linear or branched saturated or unsaturated C1-7 alkyl, (C1-7)alkoxycarbonyl(C1-7)alkyl, phenyl, phenyl(C1-5)alkyl or phenylcarbonylmethyl; and each R2 and R2 is independently H, linear or branched saturated or unsaturated C1-7 alkyl or phenyl, or R2 and R3 may form a ring together with C1-5 alkylene. A pharmaceutical composition for treating and preventing rheumatoid arthritis comprises the 1,2,4-thiadiazolidine-3,5-dione compound of the formula(1) or a pharmaceutically acceptable salt thereof as an effective ingredient.
Abstract:
An anticancer composition comprising 3-methyl-(O-substituted oximino)-pyrazolin-5-one derivatives is provided, which derivatives inhibit activity of CDC25B enzyme which participates in cell differentiation and is overexpressed in cancer cells. The anticancer composition comprises 3-methyl-(O-substituted oximino)-pyrazolin-5-one derivatives represented by formula (1), and pharmaceutically acceptable salts thereof, wherein R1 is C1-C4 alkyl or substituted phenyl with a substituent that is one or more selected from hydrogen, halogen atom, C1-C4 alkyl, C1-C4 alkoxy, C2-C4 acyl and nitro; and R2 is C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 acyl, methanesulfonyl, toluenesulfonyl, C1-C4 alkoxycarbonylmethyl, carboxymethyl or inorganic metal or organic amine salts of carboxymethyl.
Abstract:
PURPOSE: A pharmaceutical composition containing myxochelin-A which exhibits excellent anticancer activity against human cancer cells, together with excellent antioxidant activity as a main component is provided which can be effectively used as an effective antioxidant and anticancer agent. CONSTITUTION: The pharmaceutical composition contains myxochelin-A of formula 1 obtained by being separated from myxobacteria or being chemically synthesized or semisynthesized. The myxochelin-A is purely separated by the steps of: separating a biomass and absorption resin by culturing Angiococcus disciformis strains as myxobacteria in the presence of absorption resin and centrifuging a culture solution; adding an organic solvent, preferably a mixed solvent of acetone and methanol; extracting and filtering to remove the biomass and absorption resin; preparing an active fraction by concentrating the filtrate under reduced pressure and extracting a crude extract in an organic solvent; and successively performing silica gel liquid chromatography and recycling preparative HPLC.
Abstract:
PURPOSE: Provided is 4-O-(2-(N,N-dialkylamino)- 2-deoxy-4,6-O,O- (alkenylidene or alkynylidene)-beta-D- glucosyl)-4-O- dimethyl-epi-podophyllotoxin compound which is used in the treatment of cancers. Also, its producing method and an anticancer composition containing the same compounds are provided. CONSTITUTION: The 4-O-(2-(N,N-dialkylamino)- 2-deoxy-4,6-O,O- (alkenylidene or alkynylidene)-beta-D- glucosyl)-4-O- demethyl-epi-podophyllotoxin compound is represented by formula (1), in which R1 and R2 are individually hydrogen, C1 to C10 alkyl or C5 to C10 cycloalkyl or forms together C4 to C10 ring compounds having nitrogen atom; and R3 is linear or branched C1 to C8 alkyl, alkoxy, alkoxyalkyl or vinyl having aryl substituents, ethynyl, allyl, C3 to C10 cycloalkyl, C5 to C10 cycloalkenyl or C5 to C10 cycloalkynyl. The compound is produced by reacting a compound of formula (2) with aldehyde(3) or acetal of formula (4) in the presence of acid catalysts to produce a compound of formula (5); removing amino protecting group of formula (5) to produce compound of formula (6); and alkylation reacting the compound of formula (6) in the presence of reductase to produce the compounds of formula (1).
Abstract:
본 발명은 3′-치환-3′-데옥시티미딘, 특히 AZT의 제조에서 중간체로 사용되는 5′-히드록시 보호된 2,3′-안히드로티미딘의 제조 방법에 관한 것으로, 하기 일반식(1)의 5′-히드록시 보호-티미딘을 치환 또는 비치환 티오카르보닐디이미다졸과 반응시켜 하기 일반식(2)의 5′-히드록시 보호-3′-0-이미다졸릴티오카르보닐티미딘을 제조하고, 일반식(2)의 화합물을 염기 촉매 존재 또는 비존재하에 가열하는 단계를 포함하는 방법에 의하면, 3′-치환-3′-데옥시티미딘의 제조시 5′-히드록시 보호기가 산과 염기 조건하에서도 안정한 하기 일반식(3)의 5′-히드록시 보호된 2,3′-안히드로티미딘을 경제적으로 대량 합성할 수 있다.
Abstract:
본 발명은 3-메칠-(O-치환된 옥시이미노)-피라졸린-5-온 유도체를 함유하는 항암제에 관한 것으로서, 더욱 상세하게는 세포분열에 결정적으로 작용하는 CDC25B의 탈인산화효소에 대한 탁월한 저해활성을 가지고 있는 다음 화학식 1로 표시되는 (O-치환된 옥시이미노)-피라졸린-5-온 유도체가 유효활성 성분으로 함유되어 있는 항암제에 관한 것이다.
상기 화학식 1에서, R 1 및 R 2 는 각각 발명의 상세한 설명에서 정의한 바와 같다.
Abstract:
PURPOSE: A π-conjugate compound for molecular electronic devices is provided. The compound can be self-assembled, has easy electron-delocalized structure by π -conjugate linkage of total molecules, and properties to easily trap electron by electric filed produced from the outside because cation is contained within the molecules. CONSTITUTION: A π-conjugate compound for molecular electronic devices is characterized by being represented by the formula(1) of R¬1-Z- £Redox|¬1-Z-R¬2, containing center £Redox| capable of oxidation/reduction, and being connected to aromatic compounds directly or via acetylene bond,, wherein R1 is selected from benzene, CH3COS-benzene, CH3SS-benzene and SiS-benzene; R2 is selected from S-COCH3-benzene and (S-benzene)2; Z is single bond or triple bond; £Redox|1 is selected from X-N+R3-benzene, N+R3-naphthalene, and N+CH3CH3R3-naphthalene; R3 is selected from hydrogen, C1-C4 alkyl and benzyl; X- is selected from I-, Cl-, Br-, CF3SO3, CH3-benzene-SO3-, C12H25-benzene-SO3-, BF4-, PF6- and SbF6-.